Genfit SA
XUP
Company Profile
Business description
Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements to fund the further development of its products. It has one segment, the research and development of medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.
Contact
885, Avenue Eugene Avinee
Parc Eurasante
Loos59120
FRAT: +33 320164000
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
192
Stocks News & Analysis
stocks
Australia’s largest gold miner downgraded on a falling gold price
A cooling gold price sees fair value cuts across the board.
stocks
Cheap ASX share pays a heavy price for NRL rights
Growth has slowed amid increased competition for viewers and content.
stocks
The World Cup stock you’ve never heard of
This ASX stock is kicking goals at the FIFA World Cup.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,990.60 | 5.80 | -0.06% |
| CAC 40 | 8,338.97 | 12.35 | 0.15% |
| DAX 40 | 25,067.09 | 51.18 | -0.20% |
| Dow JONES (US) | 52,637.01 | 149.60 | 0.29% |
| FTSE 100 | 10,497.29 | 24.84 | 0.24% |
| HKSE | 24,191.79 | 16.67 | 0.07% |
| NASDAQ | 26,281.61 | 74.72 | 0.29% |
| Nikkei 225 | 67,013.66 | 1,544.07 | -2.25% |
| NZX 50 Index | 13,723.20 | 62.47 | -0.45% |
| S&P 500 | 7,575.39 | 31.75 | 0.42% |
| S&P/ASX 200 | 8,795.90 | 0.90 | -0.01% |
| SSE Composite Index | 3,934.16 | 62.00 | -1.55% |